• Something wrong with this record ?

The impact of the temporal sequence of cranial radiotherapy and platin-based chemotherapy on hearing impairment in pediatric and adolescent CNS and head-and-neck cancer patients: A report from the PanCareLIFE consortium

S. Scobioala, R. Parfitt, P. Matulat, J. Byrne, T. Langer, FM. Troschel, AE. Hesping, E. Clemens, P. Kaatsch, D. Grabow, M. Kaiser, C. Spix, LC. Kremer, G. Calaminus, K. Baust, CE. Kuehni, A. Weiss, S. Strebel, R. Kuonen, S. Elsner, R. Haupt, ML....

. 2024 ; 154 (2) : 320-331. [pub] 20230915

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000093

Grant support
602030 EU FP7 Project
FP7-HEALTH-2013-INNOVATION-1 HEALTH.2013.2.4.1-3
Swiss Cancer League
KLS-3412-02-2014 Swiss Cancer Research Foundation
HSR-4951-11-2019 Swiss Cancer Research Foundation
KLS/KFS-5711-01-2022 Swiss Cancer Research Foundation

The impact of the temporal sequence by which cranial radiotherapy (CRT) and platin-based chemotherapy (PCth) are administered on sensorineural hearing loss (SNHL) in pediatric and adolescent central nervous system (CNS) and head-and-neck (HN) cancer patients has not yet been studied in detail. We examined the ototoxic effects of sequentially applied CRT and PCth. This study included children and adolescents with CNS and HN tumors who participated in the multicountry PanCareLIFE (PCL) consortium. Audiological outcomes were compared between patients who received CRT prior to PCth and those who received it afterwards. The incidence, degree and posttreatment progression of SNHL, defined as Muenster classification grade ≥MS2b, were evaluated in 141 patients. One hundred and nineteen patients were included in a time-to-onset analysis. Eighty-eight patients received CRT prior to PCth (Group 1) and 53 patients received PCth before CRT (Group 2). Over a median follow-up time of 1.6 years, 72.7% of patients in Group 1 experienced SNHL ≥ MS2b compared to 33.9% in Group 2 (P < .01). A time-to-onset analysis was performed for 74 patients from Group 1 and 45 patients from Group 2. Median time to hearing loss (HL) ≥ MS2b was 1.2 years in Group 1 and 4.4 years in Group 2 (P < .01). Thus, audiological outcomes were better for patients who received CRT after PCth than before. This finding should be further evaluated and considered within clinical practice in order to minimize hearing loss in children and adolescents with CNS and HN tumors.

Academisch Medisch Centrum bij de Universiteit van Amsterdam Amsterdam The Netherlands

Boyne Research Institute Drogheda Ireland

Childhood Cancer Research Group Danish Cancer Society Research Center Copenhagen Denmark

Clinic for Radiotherapy Radiooncology University Hospital Muenster Muenster Germany

Department for Phoniatrics and Pedaudiology University Hospital Muenster UKM Germany

Department of Paediatric Oncology University Hospital Brno Brno Czech Republic

Department of Pediatric Hematology and Oncology University Hospital Bonn Bonn Germany

Department of Pediatrics Aarhus University Hospital Aarhus Denmark

Department of Pediatrics Inselspital Bern University Hospital University of Bern Bern Switzerland

Department of Pediatrics Jena University Hospital Jena Germany

Division of Childhood Cancer Epidemiology German Childhood Cancer Registry Institute of Medical Biostatistics Epidemiology and Informatics University Medical Center of the Johannes Gutenberg University Mainz Mainz Germany

DOPO Clinic and Neuroncology Unit Department of Hematology Oncology IRCCS Istituto Giannina Gaslini Genoa Italy

Erasmus University Medical Centre Rotterdam The Netherlands

German Childhood Cancer Registry Institute of Medical Biostatistics Epidemiology and Informatics University Medical Center of the Johannes Gutenberg University Mainz Mainz Germany

Institute of Clinical Pharmacology Brandenburg Medical School Rüdersdorf Germany

Institute of Social and Preventive Medicine University of Bern Bern Switzerland

International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic

Motol Teaching Hospital Prague Czech Republic

Pediatric and Adolescent Medicine Juliane Marie Centre Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Pediatric Hematology and Oncology Medical University of Graz Graz Austria

Pediatric Hematology and Oncology University Children's Hospital Muenster Muenster Germany

Pediatric Oncology and Hematology University Hospital for Children and Adolescents University of Luebeck Luebeck Germany

Pediatric Oncology University Hospital Erlangen Erlangen Germany

Pediatrics 5 Center for Pediatric Adolescent and Women's Medicine Stuttgart Cancer Center Klinikum Stuttgart Olgahospital Stuttgart Germany

Princess Maxima Center for Pediatric Oncology and University of Utrecht Utrecht The Netherlands

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000093
003      
CZ-PrNML
005      
20240219145133.0
007      
ta
008      
240109s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34732 $2 doi
035    __
$a (PubMed)37715472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Scobioala, Sergiu $u Clinic for Radiotherapy, Radiooncology University Hospital Muenster, Muenster, Germany $1 https://orcid.org/0000000196223169
245    14
$a The impact of the temporal sequence of cranial radiotherapy and platin-based chemotherapy on hearing impairment in pediatric and adolescent CNS and head-and-neck cancer patients: A report from the PanCareLIFE consortium / $c S. Scobioala, R. Parfitt, P. Matulat, J. Byrne, T. Langer, FM. Troschel, AE. Hesping, E. Clemens, P. Kaatsch, D. Grabow, M. Kaiser, C. Spix, LC. Kremer, G. Calaminus, K. Baust, CE. Kuehni, A. Weiss, S. Strebel, R. Kuonen, S. Elsner, R. Haupt, ML. Garré, B. Gruhn, T. Kepak, K. Kepakova, JF. Winther, L. Kenborg, C. Rechnitzer, H. Hasle, J. Kruseova, A. Luks, H. Lackner, S. Bielack, JD. Beck, H. Jürgens, MM. van den Heuvel-Eibrink, O. Zolk, HT. Eich, A. Am Zehnhoff-Dinnesen, PanCareLIFE Consortium
520    9_
$a The impact of the temporal sequence by which cranial radiotherapy (CRT) and platin-based chemotherapy (PCth) are administered on sensorineural hearing loss (SNHL) in pediatric and adolescent central nervous system (CNS) and head-and-neck (HN) cancer patients has not yet been studied in detail. We examined the ototoxic effects of sequentially applied CRT and PCth. This study included children and adolescents with CNS and HN tumors who participated in the multicountry PanCareLIFE (PCL) consortium. Audiological outcomes were compared between patients who received CRT prior to PCth and those who received it afterwards. The incidence, degree and posttreatment progression of SNHL, defined as Muenster classification grade ≥MS2b, were evaluated in 141 patients. One hundred and nineteen patients were included in a time-to-onset analysis. Eighty-eight patients received CRT prior to PCth (Group 1) and 53 patients received PCth before CRT (Group 2). Over a median follow-up time of 1.6 years, 72.7% of patients in Group 1 experienced SNHL ≥ MS2b compared to 33.9% in Group 2 (P < .01). A time-to-onset analysis was performed for 74 patients from Group 1 and 45 patients from Group 2. Median time to hearing loss (HL) ≥ MS2b was 1.2 years in Group 1 and 4.4 years in Group 2 (P < .01). Thus, audiological outcomes were better for patients who received CRT after PCth than before. This finding should be further evaluated and considered within clinical practice in order to minimize hearing loss in children and adolescents with CNS and HN tumors.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a mladiství $7 D000293
650    12
$a nedoslýchavost $x chemicky indukované $x epidemiologie $7 D034381
650    _2
$a centrální nervový systém $7 D002490
650    12
$a percepční nedoslýchavost $x chemicky indukované $x epidemiologie $7 D006319
650    _2
$a kraniální ozáření $7 D016371
650    12
$a nádory hlavy a krku $x farmakoterapie $x radioterapie $7 D006258
655    _2
$a časopisecké články $7 D016428
700    1_
$a Parfitt, Ross $u Department for Phoniatrics and Pedaudiology, University Hospital, Muenster, UKM, Germany
700    1_
$a Matulat, Peter $u Department for Phoniatrics and Pedaudiology, University Hospital, Muenster, UKM, Germany
700    1_
$a Byrne, Julianne $u Boyne Research Institute, Drogheda, Ireland $1 https://orcid.org/0000000210703004
700    1_
$a Langer, Thorsten $u Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, University of Luebeck, Luebeck, Germany
700    1_
$a Troschel, Fabian M $u Clinic for Radiotherapy, Radiooncology University Hospital Muenster, Muenster, Germany
700    1_
$a Hesping, Amélie E $u Department for Phoniatrics and Pedaudiology, University Hospital, Muenster, UKM, Germany
700    1_
$a Clemens, Eva $u Erasmus University Medical Centre (EMC), Rotterdam, The Netherlands
700    1_
$a Kaatsch, Peter $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Grabow, Desiree $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Kaiser, Melanie $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Spix, Claudia $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Kremer, Leontien C $u Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC), Amsterdam, The Netherlands $u Princess Maxima Center for Pediatric Oncology (PMC), and University of Utrecht, Utrecht, The Netherlands
700    1_
$a Calaminus, Gabriele $u Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany $u Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany
700    1_
$a Baust, Katja $u Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany $u Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany
700    1_
$a Kuehni, Claudia E $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland $u Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
700    1_
$a Weiss, Annette $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
700    1_
$a Strebel, Sven $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
700    1_
$a Kuonen, Rahel $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland $u Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
700    1_
$a Elsner, Susanne $u Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, University of Luebeck, Luebeck, Germany
700    1_
$a Haupt, Riccardo $u DOPO Clinic and Neuroncology Unit, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini (IGG), Genoa, Italy
700    1_
$a Garré, Maria-Luisa $u DOPO Clinic and Neuroncology Unit, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini (IGG), Genoa, Italy
700    1_
$a Gruhn, Bernd $u Department of Pediatrics, Jena University Hospital, Jena, Germany
700    1_
$a Kepak, Tomas $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Kepáková, Kateřina, $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Paediatric Oncology, University Hospital Brno, Brno, Czech Republic $d 1972- $7 mzk2004246514
700    1_
$a Winther, Jeanette Falck $u Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark $1 https://orcid.org/0000000234405108
700    1_
$a Kenborg, Line $u Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark $1 https://orcid.org/0000000235846570
700    1_
$a Rechnitzer, Catherine $u Pediatric and Adolescent Medicine, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
700    1_
$a Hasle, Henrik $u Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Kruseova, Jarmila $u Motol Teaching Hospital, Prague, Czech Republic
700    1_
$a Luks, Ales $u Motol Teaching Hospital, Prague, Czech Republic
700    1_
$a Lackner, Herwig $u Pediatric Hematology and Oncology, Medical University of Graz, Graz, Austria
700    1_
$a Bielack, Stefan $u Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent, and Women's Medicine, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany
700    1_
$a Beck, Jörn-Dirk $u Pediatric Oncology, University Hospital Erlangen, Erlangen, Germany
700    1_
$a Jürgens, Heribert $u Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
700    1_
$a van den Heuvel-Eibrink, Marry M $u Princess Maxima Center for Pediatric Oncology (PMC), and University of Utrecht, Utrecht, The Netherlands
700    1_
$a Zolk, Oliver $u Institute of Clinical Pharmacology, Brandenburg Medical School, Rüdersdorf, Germany
700    1_
$a Eich, Hans Theodor $u Clinic for Radiotherapy, Radiooncology University Hospital Muenster, Muenster, Germany
700    1_
$a Am Zehnhoff-Dinnesen, Antoinette $u Department for Phoniatrics and Pedaudiology, University Hospital, Muenster, UKM, Germany
710    2_
$a PanCareLIFE Consortium
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 154, č. 2 (2024), s. 320-331
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37715472 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240219145131 $b ABA008
999    __
$a ok $b bmc $g 2049031 $s 1209787
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 154 $c 2 $d 320-331 $e 20230915 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a 602030 $p EU FP7 Project
GRA    __
$p FP7-HEALTH-2013-INNOVATION-1 HEALTH.2013.2.4.1-3
GRA    __
$p Swiss Cancer League
GRA    __
$a KLS-3412-02-2014 $p Swiss Cancer Research Foundation
GRA    __
$a HSR-4951-11-2019 $p Swiss Cancer Research Foundation
GRA    __
$a KLS/KFS-5711-01-2022 $p Swiss Cancer Research Foundation
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options